146 results about "Rat model" patented technology

The invention discloses a polypeptide with blood pressure lowering and oxidation resisting effects as well as a related product and application thereof, and relates to the technical field of biology. According to the invention, casein is taken as a raw material, and the milk-derived active peptide ALPQY is successfully obtained through multi-enzyme hydrolysis, separation, purification and identification. In-vitro activity evaluation results show that the polypeptide not only has strong ACE inhibitory activity, but also can effectively scavenge free radicals; the ACE inhibition IC50 value is 35.56 mu M, the free radical scavenging TEAC value is 1.83 mu mol TE / mu mol, and compared with similar polypeptides, the polypeptide has better ACE inhibition effect and free radical scavenging effect. In-vivo antihypertensive evaluation is carried out through a spontaneous hypertension rat model, it is also shown that the compound has a good antihypertensive effect, and the compound can be used for preparing products related to antihypertensive and / or antioxidation.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

The present application relates to the field of model construction, in particular to a kind of construction method of vertebral artery compression rat model, the inner diameter and blood flow velocity of normal rat vertebral artery are obtained by ultrasonic detection;Anesthetize rat, skin preparation, disinfection, incision, expose vertebral artery;According to the required compression degree, select the tissue clip of corresponding specification, fix on vertebral artery, keep vertebral artery in compression state;Suture incision, disinfection, bandage;After rat awakens, daily care, feed, until incision healing;Ultrasonic detection is carried out, the inner diameter and blood flow velocity of the vertebral artery of rat model are obtained, compared with the inner diameter and blood flow velocity of the vertebral artery of the same age healthy rat or rat before modeling, whether it meets the standard of successful modeling is judged.

The invention belongs to the technical field of biomedicine, and particularly relates to an animal model and a modeling method thereof. According to the method, the northwest dryness syndrome type sub-health animal model is successfully constructed, an open model evaluation mode is adopted, and the established model is evaluated through goodness of fit; furthermore, autumn pear syrup is used for indicating that the prescription corresponds to the syndrome. The northwest dryness syndrome type sub-health target model established by the invention can provide a stable and reliable research model for external dryness syndrome essence exploration, arid region sub-health prevention and treatment, drug effect and pharmacological mechanism research of traditional Chinese medicines, prescriptions and the like with body resistance strengthening and dryness moistening effects, health product research and development and the like. An open model evaluation mode is adopted, and the higher the goodness of fit is, the closer the model to the northwest dryness syndrome type sub-health target model is. The northwest dryness syndrome type square domain dryness evil sub-health rat model is more suitable for arid region sub-health status research, and the northwest dryness syndrome type autumn cause dryness evil sub-health rat model is more suitable for autumn moistening health care research.

The invention discloses an NLRP3 inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown as a formula (NLRP3i-3) or a pharmaceutically acceptable salt thereof, the formula (I) is COCCNc1nc2c (c (= O) n (C) c (= O) n2C) n1Cc1cc (OC) ccc1N, and the chemical name is 8-((4-amino-2-methoxybenzyl)-7, 9-dimethyl-7, 9-dihydro-8H-purine-6, 8-diketone. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound in preparation of drugs for preventing and / or treating NLRP3-mediated diseases. The disease is preferably myocardial ischemia reperfusion injury. Experimental results show that the compound provided by the invention has excellent NLRP3 inhibitory activity (IC50lt, 100nM), and has high selectivity to NLRP3 inflammasomes; good pharmacokinetic characteristics are achieved in a rat body, and the bioavailability is high; in myocardial ischemia reperfusion injury models of mice and rats, the composition can significantly reduce myocardial infarction area, reduce myocardial enzyme level, alleviate inflammatory response and improve heart function; preliminary toxicological evaluation shows that the safety is good. Therefore, the compound disclosed by the invention is expected to be developed into a novel medicine for treating NLRP3 related diseases such as myocardial ischemia-reperfusion injury.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

The invention discloses an application of N6022 in improving brain injury after cardiac arrest resuscitation, and particularly relates to an application of N6022 or a derivative thereof given through a nose in improving the brain injury after cardiac arrest resuscitation and increasing the survival rate after cardiac arrest resuscitation. Compared with the prior art, the application has the advantages that the increased GSNOR enzyme activity of brain tissues after sudden cardiac arrest resuscitation can be effectively inhibited by nasal injection of N6022 into a sudden cardiac arrest resuscitation rat model; the N6022 can effectively improve the neurological function after cardiac arrest resuscitation and increase the survival rate after cardio-pulmonary resuscitation; n6022 is used for inhibiting the activity of GSNOR, so that the number of survival neurons of brain tissues after sudden cardiac arrest resuscitation can be increased; the delivery mode of the N6022 through the nose can effectively enable the N6022 to enter the brain tissue of the rat. According to the invention, a new application field of N6022 is developed, and a meaningful reference is provided for improving the cerebral function after sudden cardiac arrest resuscitation.

The invention belongs to the technical field of biological medicine, and relates to application of miRNA targeted regulation in treatment of acute respiratory distress syndrome, in particular to application of a miR-144 inhibitor in preparation of a medicine for improving glucocorticoid treatment sensitivity of an ARDS patient. Research on a lipopolysaccharide-induced ARDS rat model finds that miR-144 participates in regulation and control of glucocorticoid receptor beta (GR beta) and NF-kappa B signal pathways in the ARDS inflammatory reaction process, the number of neutrophils in alveolar lavage fluid and the level of inflammatory factors such as IL-6 and TNF-alpha can be remarkably reduced by using the miR-144 inhibitor and glucocorticoid for treatment, and the application of the miR-144 inhibitor to treatment of the pulmonary alveolar lavage fluid in the treatment of the pulmonary alveolar lavage fluid is broad. The wet-to-dry ratio and pathological injury score of lung tissues are reduced, and GR beta and NF-kappa B expression is inhibited, so that the anti-inflammatory effect of glucocorticoid is remarkably enhanced. The invention provides a treatment strategy for improving glucocorticoid resistance of ARDS patients by taking miR-144 as a target for the first time, and provides a new drug target and a technical scheme for accurate treatment of ARDS.

The invention provides a manufacturing method of a silica-induced lung injury rat model and application of Erchen decoction. A manufacturing method of a silica-induced lung injury rat model is used for researching medical application and pathological effects of Erchen decoction in treatment of silicosis, traditional Chinese medicines in the Erchen decoction comprise Pinellia ternate, dried orange peel, Poria cocos, honey-fried licorice root, dark plum and ginger, and the manufacturing method is characterized by comprising the following steps: S1, experimental animals and grouping; the invention provides a manufacturing method of a silica-induced lung injury rat model and an application of Erchen soup, and systematically verifies and deepens a microecological mechanism of silicosis on the basis of early discovery; a new accurate diagnosis and treatment target is provided; the modern breakthrough of pharmacological research of traditional Chinese medicines is realized; the dysbacteriosis type silicosis model established by the invention has the advantages of simple and convenient modeling method, good repeatability, clear pathological characteristics and clear key target spots.

The invention discloses application of EDIL-3 in preparation of a medicine for repairing blood vessels in acute lung injury and application of ISX-9 in promotion of expression of EDIL-3 in mesenchymal stem cell exosomes. It is found for the first time that ISX-9 can promote expression of EDIL-3, and EDIL-3 overexpression can improve the ALI treatment capacity of MSCs-EXO, and it is proved that the lung action strength of EDIL-3 in the mesenchymal stem cell exosome is enhanced, and the ALI treatment capacity of the mesenchymal stem cell exosome is enhanced. The scheme has been verified in cell and rat ALI models, and has potential clinical application value.

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

A method for modeling temporomandibular joint osteoarthritis, 6-week-old rats are selected, the rats are confirmed to have entered an anesthetized state before surgery, the rat's mandibular incisors are first checked and confirmed to be normal, the first arm of the device is sleeved on one side of the mandibular incisor, and the palatal side of the maxillary incisor is made to touch the slope surface of the second arm of the device, the device is checked and confirmed to not affect the rat's mandibular movement and occlusion, not significantly raise the bite, have no early contact, and the upper and lower jaw relationship is relatively stable; the device and the mandibular incisor sleeved with the device are fixed; then the rat is put back into the cage, and soft food or powdered feed is given after waking up; the device is removed after being fed for 8 weeks or more. It is verified that the condylar process of the rat changes significantly, the overall condylar process is significantly reduced, the subchondral bone is destroyed, and the expression of the cartilage matrix is also reduced. Thus, a TMJOA rat model exhibiting mandibular retrusion is formed.

The invention relates to a construction method and application of a spontaneous and persistent ventricular tachycardia animal model, in particular to a spontaneous and persistent ventricular tachycardia rat model based on MYL4 gene defect and myocardial infarction induction. The model is constructed by utilizing the synergistic effect of double pathological factors of MYL4 gene conserved gene defects and acquired myocardial infarction, the induction rate of the model is greater than or equal to 90%, the spontaneous duration time reaches 1-3 min, and the method is obviously superior to an existing construction method for inducing the spontaneous and continuous ventricular tachycardia model. The model can simulate the pathophysiological process of ventricular tachycardia after human MYL4 gene related cardiovascular diseases combined with myocardial infarction, provides general technical support for ventricular arrhythmia pathogenesis research, drug screening and medical instrument research and development, and has wide scientific research and clinical transformation value.

The invention provides a construction method of a hypertension-cerebral hypoperfusion composite cerebral small vascular disease rat model. The construction method comprises the steps of experimental animal and grouping, hypertension model induction, cerebral hypoperfusion model induction and model evaluation system. According to the model, hereditary hypertension is replaced by 'L-NAME-induced drug-induced hypertension', and the model is combined with bilateral carotid artery occlusion surgery, so that clinical common hypertension and cerebral hypoperfusion dual pathological processes are successfully simulated. Compared with an SHR model, drug-induced hypertension is adopted to replace hereditary hypertension, and the method has the remarkable advantages in the aspects of period-cost-controllability-flux, 1, the modeling period is shortened to 8 weeks, and about 2 / 3 of time is saved; (2) the cost of a single animal is less than 1 / 3 of that of SHR, and the method is suitable for large-sample and multi-batch research; (3) the dosage of the L-NAME is adjustable, and the two-way intervention research of'hypertension driving 'and'blood pressure normalization' is supported; background data of the SD rats are complete and sufficient in supply, and multi-center repeated experiments are facilitated.

The invention discloses an iRGD-modified mesenchymal stem cell outer vesicle-loaded WZ35 dual-targeting drug delivery composition, which is characterized in that rat bone marrow mesenchymal stem cell-derived extracellular vesicles are used as carriers, curcumin analogues WZ35 are loaded in the carriers, and iRGD peptides are covalently modified on the surfaces of the carriers, so that passive targeting and active targeting synergistic delivery is realized; efficient entrapment of the medicine is achieved in an extrusion or co-incubation mode, the particle size of the obtained composition is 100-200 nm, and the dispersity is good; in-vivo experiments show that compared with free WZ35, the composition has the advantages that the enrichment efficiency of WZ35 in lung tissue is remarkably improved, right ventricular systolic pressure can be effectively reduced in an anoxia-induced pulmonary arterial hypertension rat model, pulmonary vascular remodeling is improved, and the invention provides a novel efficient and safe drug delivery strategy for targeted therapy of lung diseases.

The invention discloses a method for improving autism behaviors through Npas4 expression and overexpression in a cat chat syndrome model, and belongs to the technical field of animal model construction. Selecting SD wild rats and CdCS model rats, and normally feeding and breeding the rats; the method comprises the following steps: measuring the protein concentration by adopting a BCA method, then carrying out Western Blot, then carrying out brain stereotactic injection, and finally carrying out behavioral testing. According to the invention, a CdCS rat model is established by using a CRISPR-Cas9 technology, and the model shows cognitive and social behavior disorders and medial prefrontal cortex (mPFC) neuron dendritic abnormality; in addition, an abnormally expressed gene is found in the model mouse, the research focuses on Npas4, and a new insight is possibly provided for disease treatment.

The application belongs to the technical field of biology and specifically relates to a casein phosphopeptide for promoting calcium, iron and zinc mineral absorption and improving bone health. The application obtains the casein phosphopeptide containing high-activity peptide segments by optimizing the process, and takes six mineral elements of calcium, magnesium, copper, iron, zinc and manganese as research objects. Firstly, the mineral deficiency rat model is used to evaluate the mineral utilization of the CPP. The consumption of 7mg / kg.d increases the contents of Ca, Mg, Cu, Fe, Zn and Mn in femur by 7.12%, 3.56%, 20.76%, 15.84%, 9.94% and 67.12% respectively. Secondly, the molecular docking technology is used to screen the peptide segments with calcium absorption activity from the CPP and perform function verification. The application aims to reveal the effect of the CPP in the mineral absorption and utilization from the cell and animal levels, and provide a theoretical basis for the functional development.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

This invention provides a pH-responsive immunomodulatory microneedle patch, its preparation method, and its application, belonging to the field of biomedical materials technology. This invention incorporates Zif-8 nanoparticles loaded with ChABC into GelMA hydrogel to prepare a pH-responsive immunomodulatory microneedle patch (Z@C-MN). As the patch gradually degrades, the system can continuously release Zn in a pH-responsive manner. 2+ Z@C-MN, along with ChABC, promotes in situ repair of cerebral fibrosis (SCI) after injury. Z@C-MN induces macrophage polarization towards a pro-regenerative phenotype, thereby downregulating the inflammatory response, increasing neurite length, and promoting the differentiation of neural stem cells into neurons. In vivo, Z@C-MN reduced the inflammatory microenvironment after injury and promoted angiogenesis in a rat SCI model. Furthermore, it activated axonal regeneration by inhibiting scar tissue formation and regulating CD4+. + T cell transformation supports neurogenesis.

The invention relates to a construction method of an experimental autoimmune prostatitis rat model. The construction method comprises the following steps: S1, preparing a prostate specific antigen mixture; s2, selecting male SD rats as laboratory rats, and dividing the laboratory rats into a normal saline control group, a low-dose model group and a high-dose model group; s3, continuously injecting for 7 days, allowing the normal saline control group to accept injection of 0.2 ml of normal saline every day, allowing the low-dose model group to accept injection of 0.1 ml of prostate specific antigen mixture every day, and allowing the high-dose model group to accept injection of 0.2 ml of prostate specific antigen mixture every day; and S4, continuously feeding all groups of experimental mice to the 28th day, inducing the experimental mice in the low-dose model group and the high-dose model group by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and obtaining the experimental autoimmune prostatitis rat model. The use of animals can be reduced, the cost is reduced, and the modeling efficiency and stability can be improved.

The invention belongs to the technical field of biology, and particularly relates to a scoliosis rat model construction method which comprises the following steps: S1, obtaining an experimental animal, removing the forelimb and the tail of the experimental animal, enabling the gravity direction of the experimental animal to be parallel to the spine, and obtaining a biped animal; s2, performing excision treatment on a deep paravertebral muscle group on one side of the biped animal to obtain an experimental animal with muscle mechanics imbalance; and S3, performing exercise load stimulation treatment on the experimental animal with muscle mechanics imbalance to obtain the scoliosis animal model. According to the method disclosed by the invention, the scoliosis animal model capable of highly simulating human disease characteristics is constructed by combining axial gravity load under a two-foot standing posture, structural and mechanical unbalance caused by directional unilateral deep paravertebral muscle excision and regular movement stimulation; the method can accurately and controllably induce scoliosis in a specific direction opposite to a muscle resection side, and has a wide application prospect.

The application discloses a method for preparing GHR humanized animal cells by using a CRISPR system, which comprises the following steps: designing and synthesizing sgRNA; mixing the sgRNA with a Cas9 protein to form a CRISPR-Cas9 complex; constructing donor DNA containing coding sequences of a human GHR extracellular region and a rat GHR intracellular region; injecting the CRISPR-Cas9 complex and the donor DNA into the cytoplasm or nucleus of a rat fertilized ovum to knockout the coding sequence of the extracellular region of the rat-derived GHR gene and simultaneously insert the coding sequence of the extracellular region of the human-derived GHR gene into the genome, so that the GHR humanized animal cells are obtained. The application further discloses a method for constructing a GHR humanized rat model by using the CRISPR system, and application of the GHR humanized animal cells and the GHR humanized rat model obtained by the above method in drug screening, drug development or efficacy evaluation. The application can more accurately simulate the interaction between the human GHR and growth hormone and other ligands, improves the accuracy and reliability of research, and has the advantages of simple gene editing operation, high editing efficiency, strong specificity, low off-target effect and wide application range.

The application discloses a compound capable of treating gout, which is a compound shown in a general formula (I) or a pharmaceutically acceptable salt thereof, and the compound can reduce the serum uric acid level of a hyperuricemia rat model, and has potential application values in anti-gout drugs, anti-hyperuricemia drugs and the like.

The present invention belongs to the technical field of animal modeling. Particularly disclosed are a PKHD1L1 gene point mutation rat model, a construction method therefor, and a detection method therefor. In the present invention, a murine P.L867S is knocked into the PKHD1L1 gene on the basis of a CRISPR / Cas9 system, and a point mutation is performed to change corresponding bases from TTA to TCA, such that a PKHD1L1 point mutation rat is constructed and obtained. The rat model can be further applied in various research scenarios such as epilepsy pathogenesis, design of a novel anti-epileptic drug and the like. The present invention provides use of a method for detecting cortical excitability abnormity in detecting a phenotype of an epilepsy animal model. In the present invention, after the animal model is constructed and obtained, a somatosensory evoked potential method is further adopted to detect the presence of a phenotype of cortical excitability abnormity and thereby confirm whether the model is successfully constructed or not. The present invention can be used for detecting cortical excitability abnormity, and can also be used for verifying the effectiveness of a related drug or treatment.

This application proposes a traditional Chinese medicine composition and preparation method for treating atrophic gastritis of spleen deficiency and blood stasis type, involving the field of traditional Chinese medicine. It utilizes Bupleurum chinense, stir-fried Paeonia lactiflora, Citrus reticulata peel, Pinellia ternata, Codonopsis pilosula, Poria cocos, stir-fried Atractylodes macrocephala, prepared Glycyrrhiza uralensis, Agrimonia pilosa, and Curcuma zedoaria, and establishes a water extraction and decoction preparation process. A rat model of precancerous gastric lesions was established using MNNG combined with multiple factors. Normal control group, model group, folic acid group, and traditional Chinese medicine group were set up to observe the morphological and pathological changes of the gastric mucosa. The results showed that the traditional Chinese medicine composition can reduce gastric mucosal atrophy, inflammatory cell infiltration, and fibrous tissue hyperplasia, alleviate intestinal metaplasia, downregulate the expression of AKT and mTOR proteins in the gastric mucosa, and inhibit abnormal mucosal proliferation. Its effect is superior to that of folic acid, providing experimental evidence for clinical treatment.

The invention belongs to the field of analytical chemistry, and provides a method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry, differentiated pretreatment schemes are designed aiming at different biological matrixes such as excrement, serum, colon tissue and NCM460 inflammatory cells through a liquid chromatography-tandem mass spectrometry technology, matrix interference is effectively eliminated, and the method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry is provided. A quantitative analysis method with high sensitivity and high selectivity is established; the method is successfully applied to an ulcerative colitis (UC) rat model and a lipopolysaccharide (LPS)-induced NCM460 inflammation model, and a technical means is provided for revealing a metabolic regulation mechanism of medicine intervention on UC; the method solves the technical problem that various metabolites in a tryptophan metabolic pathway are difficult to detect in the prior art, is suitable for metabolic mechanism research, drug intervention effect evaluation and large-scale detection of clinical samples of inflammatory bowel diseases such as UC, and provides a technical basis for systematic research of a tryptophan metabolic network.

The application provides application of a CFTR corrector in preparation of a drug for treating mammary gland hyperplasia, and belongs to the field of biopharmacy.The application creatively finds, through non-clinical pharmacodynamics test, that a compound represented by formula I, tizacatol, can significantly reduce the nipple diameter, height and uterus index of a mammary gland hyperplasia rat model, relieve mammary gland hyperplasia, and improve the content level of E2 and PROG in serum, and has a good treatment effect in treating mammary gland hyperplasia, and has the potential of being applied in preparation of a drug for treating mammary gland hyperplasia.

The invention relates to the field of biological medicines, and discloses application of gynostemma pentaphylla exosomes in preparation of myocardial protection medicines. The medicine comprises a medicine for treating myocardial injury after myocardial infarction; a drug for improving myocardial cell dysfunction in a sub-health state; and myocardial health-care drugs. According to the application, the myocardial protection effect of the gynostemma pentaphyllum exosome is found for the first time, and in a rat myocardial infarction reperfusion model, the gynostemma pentaphyllum exosome remarkably inhibits and reduces cell apoptosis and down-regulates alpha-SMA expression, and blocks a myocardial deterioration process. The recovery effect on the heart function is equivalent to that of a small molecular medicine trimetazidine, and is obviously better than that of gypenoside.

Provided is an Alzheimer's disease rat model or a tissue or cell thereof, which comprises a chimeric APP gene encoding a modified APP and use thereof.